Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Cardiotoxicity 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Echocardiography 14Doxorubicin 10Exercise 8Electrocardiography 7Trastuzumab 6Cyclophosphamide 5Carvedilol 5Docetaxel 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Social Determinants of Health 2Silymarin 2Magnetic Resonance Spectroscopy 2Ivabradine 2High-Intensity Interval Training 2Exercise Test 2Chemoradiotherapy 2Blood Specimen Collection 2Bisoprolol 2Antineoplastic Agents 2Anthracyclines 2sulforaphane 1schizandrin 1pegfilgrastim 1nicotinamide-beta-riboside 1mitoquinone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cardiotoxicity × Fluorophotometry × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡